Researchers reveal that CD4+ T cells can kill cancer cells lacking MHC I by triggering ferroptosis, challenging established ...

T cells are pivotal mediators of the adaptive immune response, with cytotoxic CD8+ T lymphocytes recognising peptides displayed by MHC class I molecules. This antigen presentation process involves the ...

In a paradigm breaking study, Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine (BCM) and his team, in collaboration with Drs. Arul Chinnaiyan, S ...

ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE ® SL Self-Loading MHC Class I Monomers. The novel reagents for antigen-specific CD8+ T ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Efficacy and safety of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A prospective, single-arm, phase II trial. Serplulimab versus ...